Ignite Creation Date:
2024-05-06 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06118645
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-07
First Post:
2023-09-10
Brief Title:
Cadonilimab Paclitaxel Albumin-bound Treat Advanced Gastric Adenocarcinoma With PD-L1 Inhibitors Resistance
Sponsor:
China Medical University China
Organization:
China Medical University China
Study Overview
Official Title:
An Open Multicenter Phase II Study of Cadonilimab Combined With Paclitaxel Albumin-bound in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-L1 Inhibitors Resistance
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cadonilimab combined with paclitaxel albumin-bound treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-L1 inhibitors resistance
Detailed Description:
An open multicenter Phase II study of cadonilimab combined with paclitaxel albumin-bound in the treatment of advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma that has failed prior treatment with PD-L1 inhibitors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None